Diagnosis and treatment lung damage in systemic scleroderma
https://doi.org/10.30629/0023-2149-2020-98-3-185-196
Abstract
The progressing system sclerosis (PSS), M34.0 according to IСД-10 — an autoimmune disease with characteristic spastic vascular reactions as Reynaud’s syndrome and obliterating endarteritis with ischemic violations at which the specific frustration which are followed by activation of a fibrosis and excess adjournment of collagen in fabrics develop. The progressing current of PSS leads to development of irreversible fibrous changes of skin, the musculoskeletal device, internals (lungs, heart, a digestive tract, kidneys), to malfunction of bodies, an disability of patients with the general bad forecast of a disease. Thanks to modern therapy severe damage of kidneys, meets at PSS more rare and changes in lungs in a clinical picture come to the forefront. Early diagnostics of PSS and the differentiated approach to treatment of a disease can change the course and prognosis of the disease considerably.
About the Author
T. N. Bilichenko
Research Institute of Pulmonology of Federal Medical Biological Agency
Russian Federation
Russian Federation
Tatyana N. Bilichenko — MD, PhD, internal medicine and pulmonology
115082, Moscow
SPIN: 4671-0084
References
1. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society AU Wells, 1 N Hirani, 2 on behalf of the British Thoracic Society Interstitial Lung Disease Guideline Group, a subgroup of the British Thoracic Society Standards of Care Committee, in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63(V):1–58. doi: 10.1136/thx.2008.101691.
2. All-Russian public organization «Association of rheumatologists of Russia» (Association of rheumatologists of Russia). Clinical recommendations diagnosis and treatment of systemic scleroderma (progressive systemic sclerosis). 2013:1–25. (in Russian)
3. Chotchaev F.R., Zykova A.S., Novikov P.I., Moiseev S.V. Diagnosis and treatment of systemic sclerosis. Klinicheskaya farmakologiya i terapiya. 2018;27(1):1–8. (in Russian)
4. Barnes J., Mayes M.D. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr. Opin. Rheumatol. 2012;24(2):165–70.
5. Hudson M., Thombs B., Baron M. et al. Time to diagnosis in systemic sclerosis: is sex a factor? Arthritis Rheum. 2009;61(2):274–8.
6. Ranque B., Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun. Rev. 2010;9(5):311–8.
7. Tyndall A.J., Bannert B., Vonk M. et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann. Rheum. Dis. 2010;69(10):1809–15.
8. Mora G.F. Systemic sclerosis: environmental factors. J. Rheumatol. 2009; 36 (11): 2383–2396.
9. Agarwal S.K., Reveille J.D. The genetics of scleroderma (systemic sclerosis). Curr. Opin. Rheumatol. 2010;22(2):133–8.
10. Ananyeva L.P. New classification criteria for systemic scleroderma (lecture). Nauchno-prakticheskaya revmatologiya. 2013;51(5):539– 44. (in Russian)
11. Al-Dhaher F.F., Pope J.E., Ouimet J.M. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin. Arthritis Rheum. 2010;39(4):269–77.
12. Sulli A., Ruaro B., Alessandri E. et al. Correlations between nailfold microangiopathy severity, finger dermal thickness and fingertip blood perfusion in systemic sclerosis patients. Ann. Rheum. Dis. 2014;73(1):247–51.
13. Akesson A., Hesselstrand R., Scheja A. et al. Longitudinal development of skin involvement and reliability of high frequency ultrasound in systemic sclerosis. Ann. Rheum. Dis. 2004;63(7):791–6.
14. Clements P., Lachenbruch P., Siebold J. et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J. Rheumatol. 1995;22(7):1281–5.
15. Hesselstrand R., Scheja A., Wildt M. et al. High-frequency ultrasound of skin involvement in systemic sclerosis reflects oedema, extension and severity in earlydisease. Rheumatology (Oxford). 2008;47(1):84–7.
16. Mazurov V.I., Belyaeva I.B., Zotkin E.G. Diffuse diseases of connective tissue. A guide for doctors. Publisher: «Special Publishing House Of Medical Books». 2011. ISBN: 978-5-91894-005-1. (in Russian)
17. Guseva N.G. Systemic scleroderma: clinic, diagnosis, treatment. Rossijskij zhurnal kozhnyh i venericheskih boleznej. 2002;4:5–15. (in Russian)
18. Ilkovich M.M., Kokosov A.N. Interstitial lung diseases. SPb: Normalizat, 2005:231–42. (in Russian)
19. Tyurin I.E. Computed tomography of the chest cavity. ELBI-SPb. 2003:324–30. (in Russian)
20. Teplova L.V., Anan’eva L.P., Lesnyak V.L., Starovoitova M.N. Systemic sclerosis with interstitial lung involvement: clinical characteristics of patients without lung disease. Nauchno-prakticheskaya revmatologiya. 2010;3:23–25. (in Russian)
21. Nevskaya T.A., Guseva N.G, Radens’k-Lopovok S.G., Speransky A.I. T-cell immune disorders in early systemic scleroderma. Nauchno-prakticheskaya revmatologiya. 2006; 4: 35–42. (in Russian)
22. Nasonov E.L. The National manual of rheumatology. Ed. by E.L. Nasonov. M.: GEOTAR-Media, 2010:320.
23. Guseva N.G., Anikina N. In. Shcherbakov A.B. Application capoten in systemic sclerosis. Terapevticheskij arhiv. 1992;5:100–2. (in Russian)
24. Penn H., Howie A.J., Kingdon E.J. et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM. 2007; 100(8):485–94.
25. Teixeira L., Mouthon L., Mahr A. et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann. Rheum. Dis. 2008;67(1):110–6.
26. Panasyuk A.F. Pathogenetic significance of violations of the metabolism of fibroblasts in systemic sclerosis. Abstract. dis. ... doctor of biology. M., 1989: 30. (in Russian)
27. LeRoy E.C., Black C., Fleischmayer R. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 1988;15:202–5.
28. Herrick A.L. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat. Rev. Rheumatol. 2012;8(8):469–79.
29. Clinical recommendations. Progressive systemic sclerosis (systemic scleroderma) ICD 10: M34.0 approval Year (frequency of review): 2016 (review every 2 years) ID: КР254 URL: Professional associations: Association of rheumatologists.
30. Desbois A.C., Cacoub P., Systemic sclerosis: An update in 2016, Autoimmun. Rev. 2016. doi: dx.doi.org/10.1016/j.autrev.2016.01.007.
Review
For citations:
Bilichenko T.N. Diagnosis and treatment lung damage in systemic scleroderma. Clinical Medicine (Russian Journal). 2020;98(3):185-196. (In Russ.) https://doi.org/10.30629/0023-2149-2020-98-3-185-196
Views:
1160
Email this article 